Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“The administration of montelukast caused a reduction in elevated interleukin (IL)-4, IL-13, eotaxin, immunoglobulin (Ig), inflammatory cell infiltration into the airways, and mucus production after repeated OVA challenges.”
International immunopharmacology • 2013 | View Paper
“Pretreatment with MK or MP before OVA exposure inhibited late airway response (LAR) and reduced cellular infiltration into the bronchial submucosa after the triple OVA.”
Journal of Pharmacology and Experimental Therapeutics • 2005 | View Paper
“A combination of all three compounds (mepyramine, methysergide and montelukast ) reduced ovalbumin‐induced microvascular leakage in airway tissue to basal levels (70 – 78%) and almost completely inhibited bronchospasm (92%).”